- Report
- October 2024
- 199 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- May 2024
- 135 Pages
Global
From €6170EUR$6,499USD£5,204GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1899EUR$2,000USD£1,602GBP
- Report
- January 2022
- 200 Pages
Global
From €7120EUR$7,500USD£6,006GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- January 2024
- 296 Pages
Global
€4742EUR$4,995USD£4,000GBP
The Aortic Aneurysm Drug market is a subset of the Cardiovascular Drugs market, which focuses on treatments for diseases and conditions of the heart and blood vessels. Aortic aneurysms are a type of cardiovascular disease in which the aorta, the largest artery in the body, becomes abnormally enlarged. Aortic aneurysm drugs are used to reduce the risk of rupture and to treat the symptoms of the condition. These drugs include beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and statins.
The Aortic Aneurysm Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Pfizer, Merck, Sanofi, Novartis, and Bristol-Myers Squibb. Other companies in the market include AstraZeneca, GlaxoSmithKline, Bayer, and Eli Lilly. Show Less Read more